Trial Profile
Phase I study of Respiratory Syncytial Virus (RSV) Neutralizing Monoclonal Antibody (MK-1654) in healthy population
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Feb 2022
Price :
$35
*
At a glance
- Drugs Clesrovimab (Primary) ; Clesrovimab (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
- 01 May 2021 Status changed from recruiting to completed, according to results published in the Clinical Pharmacology in Drug Development.
- 07 Oct 2018 Results (n=152) presented at the IDWeek 2018.
- 07 Oct 2018 Results presented at the IDWeek 2018